t
On 17 December 2025, Christopher Wilks, Chief Financial Officer of ECO Animal Health Group plc, exercised 4,309 nominal cost share options. These options, granted on 12 December 2022, were satisfied through a transfer of existing ordinary shares from the ECO Animal Health Group Employee Benefit Trust. As a result, Mr. Wilks' total beneficial shareholding increased to 178,186 ordinary shares, representing approximately 0.26% of the Company's issued share capital, with the total number of ordinary shares with voting rights remaining at 67,759,671.
| Date | 18 Dec 2025 |
| Time | 07:00:08 |
| Category | Miscellaneous |
| ID | 0209M |
18 December 2025
ECO Animal Health Group plc
("ECO" or the "Company")
Exercise of Share Options and Director/PDMR Shareholdings
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that Christopher Wilks, Chief Financial Officer, has exercised 4,309 nominal cost share options granted under the Company's Deferred Bonus Share Options scheme (the "Scheme"). These share options were granted on 12 December 2022 as a deferral of one-third of Mr Wilks' bonus relating to the year ended 31 March 2022.
The exercise has been fully satisfied through the transfer of existing ordinary shares held by the ECO Animal Health Group Employee Benefit Trust ("EBT"). No new ordinary shares have been issued in connection with this transaction.
As a result of this transaction, Mr. Wilks' total beneficial shareholding in the Company is now 178,186 ordinary shares, representing approximately 0.26% of the Company's issued share capital ("ISC").
Therefore, the total number of ordinary shares with voting rights in the Company remains at 67,759,671. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Group under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
The notifications below, provided in accordance with the requirements of the UK Market Abuse Regulation, provide further details
-Ends-
For further information please contact:
|
|
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
PDMR Notification - ECO LTIP Nominal Cost Conditional Share Awards
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||||||||
|
a. |
Name |
Christopher Wilks |
||||||||||||
|
2. |
Reason for the notification |
|||||||||||||
|
a. |
Position/status |
Chief Financial Officer
|
||||||||||||
|
b. |
Initial notification /Amendment
|
Initial notification |
||||||||||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||
|
a. |
Name |
Eco Animal Health Group Plc |
||||||||||||
|
b. |
LEI |
2138009XN9DJ3YP7OB55 |
||||||||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||||||||
|
a. |
Description of the Financial instrument, type of instrument Identification code |
Options over ordinary shares of 5p each.
GB0032036807
|
||||||||||||
|
b. |
Nature of the transaction |
1. Nominal cost share awards under the Company's Deferred Bonus Share Options ("DBS"). |
||||||||||||
|
c. |
Price(s) and volume(s) |
|
||||||||||||
|
d. |
Aggregated information Aggregated volume Price |
n/a
|
||||||||||||
|
e. |
Date of the transaction |
17 December 2025 |
||||||||||||
|
f. |
Place of the transaction |
Off Market
|
||||||||||||